BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31035033)

  • 1. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
    Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
    Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
    Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
    Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
    Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
    Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
    Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
    Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B-cell maturation antigen in multiple myeloma.
    Tai YT; Anderson KC
    Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
    Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
    Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
    Eckhert E; Hewitt R; Liedtke M
    Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-BCMA antibodies in the future management of multiple myeloma.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
    Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
    Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 18. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
    Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
    Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.